Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report)'s share price fell 8.2% on Tuesday . The stock traded as low as $28.08 and last traded at $27.72. 1,737,346 shares were traded during mid-day trading, an increase of 56% from the average session volume of 1,114,223 shares. The stock had previously closed at $30.21.
Wall Street Analyst Weigh In
Several brokerages recently weighed in on TWST. Guggenheim reaffirmed a "buy" rating and issued a $50.00 target price on shares of Twist Bioscience in a report on Tuesday, May 6th. Cowen reaffirmed a "buy" rating on shares of Twist Bioscience in a report on Monday, August 4th. JPMorgan Chase & Co. dropped their target price on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a report on Tuesday, May 6th. The Goldman Sachs Group decreased their price target on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Finally, Robert W. Baird decreased their price target on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $49.40.
Read Our Latest Stock Analysis on Twist Bioscience
Twist Bioscience Stock Performance
The firm has a market cap of $1.55 billion, a PE ratio of -17.68 and a beta of 2.36. The company has a current ratio of 3.90, a quick ratio of 4.24 and a debt-to-equity ratio of 0.03. The firm's 50 day simple moving average is $34.47 and its 200 day simple moving average is $37.99.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.07. The firm had revenue of $96.06 million for the quarter, compared to analysts' expectations of $95.52 million. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. On average, research analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.
Insider Activity
In other news, CEO Emily M. Leproust sold 1,678 shares of the company's stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $35.76, for a total transaction of $60,005.28. Following the sale, the chief executive officer directly owned 645,782 shares in the company, valued at approximately $23,093,164.32. This represents a 0.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Patrick John Finn sold 1,877 shares of the company's stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $29.75, for a total transaction of $55,840.75. Following the sale, the chief operating officer owned 240,783 shares in the company, valued at $7,163,294.25. This represents a 0.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 13,109 shares of company stock worth $425,962. 3.01% of the stock is currently owned by corporate insiders.
Institutional Trading of Twist Bioscience
Several hedge funds have recently made changes to their positions in TWST. ARK Investment Management LLC grew its holdings in Twist Bioscience by 2.5% during the 2nd quarter. ARK Investment Management LLC now owns 6,400,441 shares of the company's stock valued at $235,472,000 after purchasing an additional 158,846 shares during the last quarter. Vanguard Group Inc. grew its holdings in Twist Bioscience by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 5,867,459 shares of the company's stock valued at $230,356,000 after purchasing an additional 60,276 shares during the last quarter. William Blair Investment Management LLC grew its holdings in Twist Bioscience by 2.6% during the 2nd quarter. William Blair Investment Management LLC now owns 3,906,604 shares of the company's stock valued at $143,724,000 after purchasing an additional 99,737 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Twist Bioscience by 186.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company's stock valued at $95,883,000 after purchasing an additional 1,588,587 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in Twist Bioscience by 0.3% during the 2nd quarter. Geode Capital Management LLC now owns 1,424,377 shares of the company's stock valued at $52,410,000 after purchasing an additional 4,438 shares during the last quarter.
About Twist Bioscience
(
Get Free Report)
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Further Reading
Before you consider Twist Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Twist Bioscience wasn't on the list.
While Twist Bioscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
MarketBeat All Access